Key Metrics
10 - 15
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.95
5-Year SI
5-year SI
- 0.94 2-year SI
- 0.92 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q1
Oncology
SJR
- Q1 Oncology
- Q1 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
4 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
25%
4 to 6 months
66%
7 to 9 months
7%
Above 9 months
1%
Did you find this useful?
Thank you for your feedback.
Indexed in the following public directories
-
Web of Science -
DOAJ -
SJR
Topics Covered
- Cancer
- Western blot
- Assay
- Reactive oxygen species
- Hepatocellular carcinoma
- Lung cancer
- Autophagy
- Combined treatment
- Irradiation
- Cell cycle
- Isoliquiritigenin
- DNA damage
- Oxidative stress
- Tumor growth
- Cancer-Associated Fibroblasts
- Gene expression
- Cell migration
- Breast cancer
- Tumor microenvironment
- Colorectal cancer
Journal Specifications
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | EUR 2890 | USD 3490 | GBP 2490 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Regina Elena National Cancer Institute |
| Frequency | Continuous publication |
| Publication Start Year | 1982 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 8 |
| Article Processing Charges | EUR 2890 | USD 3490 | GBP 2490 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
Planning to publish in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway
- 18 Nov 24
- Journal of Experimental & Clinical Cancer Research
-
Full paper
MDM2 drives resistance to Osimertinib by contextually disrupting FBW7-mediated destruction of MCL-1 protein in EGFR mutant NSCLC.
- 15 Nov 24
- Journal of experimental & clinical cancer research : CR
-
Full paper
Correction: HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
- 13 Nov 24
- Journal of experimental & clinical cancer research : CR
-
Full paper
Correction: ISG15 andISGylation modulates cancer stem cell-like characteristics inpromoting tumor growth ofanaplastic thyroid carcinoma.
- 13 Nov 24
- Journal of experimental & clinical cancer research : CR
-
Full paper
Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma.
- 12 Nov 24
- Journal of experimental & clinical cancer research : CR
-
Full paper
Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
- 8 Nov 24
- Journal of Experimental & Clinical Cancer Research
Scite analysis
Powered by scite_
4k articles received 125.4k citations see all
- 4,748 Supporting
- 119,211 Mentioning
- 390 Contrasting
Editorial notices
- 117 Retractions
- 0 Withdrawals
- 214 Corrections
- 171 Errata
- 0 Expression of Concern
FAQs
How long has JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH been actively publishing?
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH has been in operation since 1982 till date.
What is the publishing frequency of JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH ?
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH published with a Continuous publication frequency.
How many articles did JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH publish last years ?
In 2023, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH published 347 articles.
What is the eISSN & pISSN for JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH ?
For JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,eISSN is 1756-9966 and pISSN is1756-9966.
What is the SJR for JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH ?
SJR for JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH is Q1.
Who is the publisher of JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH ?
BMC is the publisher of JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH.